CategoryLab Lessons

#MSCOVID19. CD20-antibodies will take time to be optimally vaccine ready.

COVID‐19 vaccine‐readiness for anti‐CD20‐depleting therapy in autoimmune diseases David Baker, Charles AK Roberts, Gareth Pryce, Angray S KangMonica Marta, Saul Reyes,Klaus Schmierer, Gavin GiovannoniSandra Amor. Clin Exp Immunol Although most autoimmune diseases are considered to be CD4 T‐cell or antibody‐mediated, many respond to CD20‐depleting antibodies that have limited influence on CD4 and...

EBV B cells make mice worse

This is ProfG’s turf, but MD2 pointed this one out and said what do you make of it?…I dont’t its profGs turf You have every thing here…EBV, microbiota, relapse what more do you want?…Replication I guess Epstein Barr virus-immortalized B lymphocytes exacerbate experimental autoimmune encephalomyelitis in xenograft mice.Polepole P, Bartenslager A, Liu Y, Petro TM...

Guestpost: Neurofilaments vs. ‘The straight-line instinct’!

Biography I am new to the blog and Barts-MS. I am Dr. Ide Smets and I am an ECTRIMS clinical fellow working in the Barts-MS team. My country of origin is Belgium which is famous for having six governments, for having a national dish that is claimed by another country (French Fries) and for going wild about cyclocross (bring it on Chris Froome ;-)). In 2018, I obtained my PhD in biomedical...

COVID-19 vaccine and ocrelizumab

The proof of the pudding is in the eating of it, not in the pudding or its concealed ingredients. Don’t take my word for it. From New York come two cases that were SARS-CoV-2 (COVID-19) antibody negative after developing COVID-19 while on ocrelizumab. Both cases were aged 39 and 42, within an age range that would be considered immune competent and therefore fully capable of forming an...

Alemtuzumab exposes lots of interesting biology. #MSCOVID19 The macrophage is important for getting rid of SARS-CoV-2

Yesterday we (MD1&MD2) and others (MS researchers) were accused of being responsible for the downfall of alemtuzumab with the regulators. This is because they (other MS researchers) have drip-fed reported adverse events like these: Immune-mediated hepatitis induced by therapy with alemtuzumab in a patient with Multiple Sclerosis. Bolte FJ, Schmidt HH, Schlevogt B.Hepatology. 2020...

Alemtuzumab Epiphany

Prof G is in a melancholic mood. Why? This week I am doing video consultations with all the volunteers who participated in the pivotal phase 3 and 10-year extension studies of the alemtuzumab clinical trials. My objectives are three-fold. Firstly, to make sure they are referred back into a routine NHS MS service and are not left floundering without follow-up. Secondly, to complete a few exit EDSS...

Providing Energy to Nerves Saves them from Damage

Read Licht‑Mayer et al. The brain is very energetically active and consumes a large amount of energy. This energy is made in small organelles inside the cells called mitochondria. There adenosine triphosphate ATP, which is a unit of cellular energy, is made. During demyelination the mitochondrial move to areas where myelin is lost as it takes alot of energy to keep the nerve firing. If they...

The #MSCOVID-19 vacccination window of ocrelizumab/rituximab and more evidence for the importance of memory B cells

Want the Quick Read. Do the stuff in Red! (SEE NEW PAPER AT THE BOTTOM) How long does it take for the vaccination window to open?DOI: 10.22541/au.159292858.82650822 As you know our initial paper on COVID-19 took a look at the biology of COVID-19 and its relationship to MS disease modifying drugs. How do MS drugs affect COVID-19. Read this paper. The answer, I think is not alot. Baker D, Amor...

Natalizumab – new insights

I view the field of MS as being ‘Before Natalizumab or BN’ and ‘After Natalizumab or AN’ this vlog provides another important insight we have obtained from the reanalysis of the data from the original phase 3 or AFFIRM study.

CoI: multiple

Translate

Categories

Recent Posts

Recent Comments

Archives